posted on 2016-03-15, 00:00authored byJohn B. Jordan, Douglas A. Whittington, Michael D. Bartberger, E. Allen Sickmier, Kui Chen, Yuan Cheng, Ted Judd
Fragment-based drug discovery (FBDD)
has become a widely used tool
in small-molecule drug discovery efforts. One of the most commonly
used biophysical methods in detecting weak binding of fragments is
nuclear magnetic resonance (NMR) spectroscopy. In particular, FBDD
performed with 19F NMR-based methods has been shown to
provide several advantages over 1H NMR using traditional
magnetization-transfer and/or two-dimensional methods. Here, we demonstrate
the utility and power of 19F-based fragment screening by
detailing the identification of a second-site fragment through 19F NMR screening that binds to a specific pocket of the aspartic
acid protease, β-secretase (BACE-1). The identification of this
second-site fragment allowed the undertaking of a fragment-linking
approach, which ultimately yielded a molecule exhibiting a more than
360-fold increase in potency while maintaining reasonable ligand efficiency
and gaining much improved selectivity over cathepsin-D (CatD). X-ray
crystallographic studies of the molecules demonstrated that the linked
fragments exhibited binding modes consistent with those predicted
from the targeted screening approach, through-space NMR data, and
molecular modeling.